These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Intra-arterial high-dose adriamycin in patients with malignant bone or soft tissue tumors. The factors in poor prognosis].
    Author: Yoh S, Takagishi N.
    Journal: Gan To Kagaku Ryoho; 1988 Aug; 15(8 Pt 2):2453-8. PubMed ID: 3415257.
    Abstract:
    Twenty-eight patients with malignant bone or soft tissue tumors were treated with preoperative and/or postoperative intra-arterial high-dose adriamycin. The antitumor effects of intra-arterial adriamycin were noted in not only primary tumor but also skip and distant metastasis (2 patients with lung metastasis). Clinical or histopathological responses were noted in 14/26 (54%) and 8/20 (40%) patients, respectively. Four patients were inoperable, but 24 patients were operable. Limb-saving procedures or amputation became subsequently feasible in 19/24 (79%) and 5/24 (21%) patients, respectively. Median follow-up of all the 28 patients was 23 months (minimum 3 months, maximum 127 months). Of the 20 patients with operable sarcomas, 11 (55%) were continuously disease-free, 3 (15%) were disease-free after treatment of a local recurrence or distant metastasis, and 5 (25%) died with multiple distant metastases. The Kaplan-Meier survival curves at 10 years showed 70% in 20 patients with operable sarcomas (66% in 8 with bone sarcomas, and 75% in 12 with soft tissue sarcomas). The initial large tumor size (greater than or equal to 10 cm diameters), poor response to intra-arterial adriamycin (less than NC* Clinically, less than II-B histopathologically), low total dose of adriamycin (less than 300 mg/m2), short total chemotherapy time (less than 6 months), and inadequate position of the tip of the catheter were the factors in poor prognosis.
    [Abstract] [Full Text] [Related] [New Search]